Morepen Laboratories Ltd
As of 20 Nov 2026, Morepen Laboratories is in Stage 2, the uptrend phase, now in week 22 (since 17 Jun 2026). It closed at ₹90.15, 38.7% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States… More about the company
Pro read
ProMOREPENLAB is about 5 months into its Stage 2 advance, 22% below its 50-day average and 39% under its 52-week high. A pause below the 50-day inside an uptrend is the weakest spot of the move until it closes back above the line.
Its relative strength is 95 of 99, a leader among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.
Stocks with a similar setup at this point in their move ran 0.6 points behind the average stock over the next 30 sessions on average, after costs, and their typical best close within 60 sessions was 14% above entry.
The trend read holds while it stays in Stage 2. A close below ₹116, its 50-day average, would put it at rest; ₹118, 20% under its 52-week high of ₹147, is where a trailing stop would sit.
Setup-score rank among Stage 2 peers: #38 of 50 in Pharmaceuticals · #47 of 61 in Health Care
Is MOREPENLAB early, or has it already run? Pro answers that for every NSE stock, after every close.
MOREPENLAB among Pharmaceuticals14th of 118 by relative strength
All 118 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | BLISSGVS | Stage 2 · wk 49 | 99 | +4.6% |
| 2 | KPL | Stage 2 · wk 44 | 99 | +20.5% |
| 3 | FREDUN | Stage 2 · wk 33 | 98 | +24.0% |
| 4 | VENUSREM | Stage 3 · wk 10 | 98 | −1.5% |
| 5 | RUBICON | Stage 3 · wk 4 | 98 | +18.7% |
| 6 | SAKAR | Stage 2 · wk 55 | 98 | +13.1% |
| 7 | BAFNAPH | Stage 2 · wk 23 | 98 | +1.9% |
| 8 | INDSWFTLAB | Stage 2 · wk 23 | 98 | −7.4% |
| …14 | MOREPENLAB | Stage 2 · wk 22 | 95 | −21.9% |
Mutual fund holdings
Held by 5 mutual funds in portfolios to October 2026: 1 active funds and 4 index funds and ETFs.
In October, among active funds: 1 opened a new position.
All 5 funds and what each did in October
Mutual funds holding MOREPENLAB: the ten largest and the month’s moves →
Morepen Laboratories: quick answers
What stage is Morepen Laboratories in?
As of 20 Nov 2026, Morepen Laboratories (MOREPENLAB) is in Stage 2, the uptrend phase. It entered Stage 2 on 17 Jun 2026 and is in week 22. What the four stages mean
Is Morepen Laboratories in an uptrend?
Yes. Morepen Laboratories is in a Stage 2 uptrend. It trades 30.7% above its 200-day average, which is rising.
How far is Morepen Laboratories from its 52-week high?
Morepen Laboratories closed at ₹90.15 on 20 Nov 2026, 38.7% below its 52-week high of ₹147. Its 52-week low is ₹33.68.
How has Morepen Laboratories performed over the past year?
As of 20 Nov 2026, Morepen Laboratories is up 93.5% over the past year and up 119.5% so far in 2026.
Which sector and industry is Morepen Laboratories in?
Morepen Laboratories is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals
About this companyHealth Care· Pharmaceuticals
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand name. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
Visit company website →All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.